The Different Types of B-Cell Therapy for MS

If you live with multiple sclerosis (MS), you’ve probably heard the phrase
“B-cell therapy” more times than you can count. These treatments have gone from
new kids on the block to some of the most commonly used, high-efficacy disease-modifying
therapies (DMTs) for MS.

But here’s the catch: “B-cell therapy” is not just one drug. There are several
different medications, schedules, and ways they’re given, and they don’t all
fit every person the same way. Think of it like choosing a car: they all get
you from point A to point B, but the right model depends on where you live,
what you can afford, and what kind of ride you want.

In this guide, we’ll break down how B-cell therapy works, the main types
available for MS, what makes them different, and how people actually feel
on these medications in day-to-day life.

What Is B-Cell Therapy, and Why Target B Cells in MS?

MS is an autoimmune condition in which the immune system attacks the myelin
coating around nerves in the brain and spinal cord. For a long time, T cells
took most of the blame. More recent research, however, showed that B cells
play a major role in MS inflammation by:

• Presenting antigens (showing “targets”) to T cells
• Producing inflammatory antibodies
• Releasing cytokines that help drive inflammation in the nervous system

B-cell therapies focus on wiping out or depleting a specific group of B cells
that carry a marker called CD20. By targeting CD20+ B cells, these drugs can
sharply reduce MS disease activity, including relapses and new MRI lesions,
and help slow disability progression in relapsing forms of MS.

The key idea: these medications reset part of the immune system, but they
don’t permanently erase B cells. Over time, B cells grow back, which is why
these drugs are given repeatedly on a schedule (every month or every six months,
depending on the specific therapy).

The Main Types of B-Cell Therapy for MS

In the U.S., B-cell therapies for MS are almost all anti-CD20 monoclonal
antibodies. Right now, the big players include:

• Ocrelizumab (Ocrevus) – IV infusion and a newer subcutaneous form
• Ofatumumab (Kesimpta) – self-injection at home
• Ublituximab (Briumvi) – newer infused therapy
• Rituximab – off-label in some centers

They all aim at CD20 on B cells, but they differ in how they’re given, how
often, their approval status, and subtle differences in how they interact
with the immune system.

Ocrelizumab (Ocrevus & Ocrevus Zunovo): Twice-a-Year B-Cell Therapy

Who it’s for

Ocrelizumab (Ocrevus) was the first B-cell therapy approved by the FDA for
both relapsing forms of MS and primary progressive MS (PPMS). That makes it
unique: it’s currently the only B-cell drug used widely for PPMS.

How it’s given

Traditionally, Ocrevus has been given as an intravenous (IV) infusion in an
infusion center twice a year after a split first dose. Each infusion takes
several hours and includes premedications to lower the risk of infusion
reactions.

In 2024, the FDA approved a subcutaneous version called Ocrevus Zunovo, which
combines ocrelizumab with hyaluronidase so it can be given as a roughly
10-minute under-the-skin injection by a healthcare professional twice a
year, with similar drug levels and efficacy compared with the IV form.

Benefits

• High efficacy in reducing relapses and MRI activity in relapsing MS
• Proven benefit in slowing disability progression in primary progressive MS
• Only twice a year after the first doses, which many people find convenient
• Now available as a much quicker subcutaneous option (Zunovo) in addition to IV

Drawbacks and safety considerations

Common issues include infusion or injection reactions (fever, chills, rash,
headache), and an increased risk of infections, especially respiratory or skin
infections. Over time, B-cell depletion can lower immunoglobulin (antibody)
levels, which may further increase infection risk.

There have also been concerns about a slightly increased rate of some cancers
(like breast cancer) in early trials, although long-term data are still being
collected and interpreted. Ocrevus is not considered safe during pregnancy,
so people who may become pregnant are advised to plan carefully with their
neurologist.

Ofatumumab (Kesimpta): Monthly Self-Injection at Home

Who it’s for

Ofatumumab (Kesimpta) is a fully human anti-CD20 antibody approved for
relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting
MS, and active secondary progressive MS.

How it’s given

Kesimpta is given as a once-monthly subcutaneous injection via an autoinjector
pen that you use at home after initial loading doses. No infusion center, no
IV lines, and no post-infusion chair time.

Studies have shown that ofatumumab can keep relapse rates low, sustain “no
evidence of disease activity” (NEDA) in many patients over several years, and
significantly reduce MRI lesion activity compared with some older oral
therapies.

Benefits

• Self-administered at home, which is ideal if you live far from an infusion center
• Monthly dosing may feel more “hands-on” and easier to remember for some people
• Strong evidence for relapse reduction and MRI disease control
• Autoinjector design can make injections easier and quicker

Drawbacks and safety considerations

The most common side effects are injection-site reactions (redness, itching,
swelling) and upper respiratory infections. Like other B-cell therapies,
Kesimpta can lower immunoglobulin levels and increase the long-term risk of
infections.

Because the injections are more frequent, you have to be comfortable managing
your own dosing schedule. Pregnancy and breastfeeding safety data are still
evolving, so planning is crucial if you’re considering starting a family.

Ublituximab (Briumvi): A Glycoengineered Newcomer

Who it’s for

Ublituximab (Briumvi) is one of the newest anti-CD20 options. The FDA approved
it in December 2022 for adults with relapsing forms of MS, including clinically
isolated syndrome, relapsing-remitting MS, and active secondary progressive
MS.

How it’s given

Briumvi is an intravenous infusion but is designed to be given more quickly
than some other infused B-cell therapies. After initial loading doses, it’s
typically given every six months.

Ublituximab is “glycoengineered,” meaning the sugar structures on the antibody
have been modified to enhance its ability to recruit natural killer cells and
more efficiently clear CD20+ B cells through antibody-dependent cellular
cytotoxicity (ADCC).

Benefits

• High efficacy in reducing relapses and new MRI lesions in clinical trials
• Relatively short infusion times compared with some other IV therapies
• Twice-yearly dosing after the initial course

Drawbacks and safety considerations

Infusion reactions and infections are again the main concerns. Long-term data
are still emerging, but so far the safety profile looks similar to other
anti-CD20 drugs, with expected risks related to immune suppression and
hypogammaglobulinemia (low antibodies).

Rituximab and Other Off-Label B-Cell Therapies

Rituximab is an older anti-CD20 antibody first used for blood cancers and some
autoimmune conditions. It’s not FDA-approved for MS, but some neurologists in
the U.S. still use it off-label, especially in health systems where it may be
more affordable or more familiar than newer drugs.

Off-label use usually relies on data from smaller studies and real-world
experience rather than large MS-specific phase III trials. Because of that,
insurance coverage and access can vary widely.

How Do Doctors Choose Between B-Cell Therapies?

If these drugs all target the same cells, why does your neurologist recommend
one over another? Choosing a B-cell therapy is a bit like matching a puzzle
piece to your specific situation. Factors often include:

• Type of MS: Ocrevus (and Ocrevus Zunovo) is currently the
  B-cell option with strong evidence for primary progressive MS, while all
  three major agents (Ocrevus, Kesimpta, Briumvi) are used for relapsing
  forms.
• How aggressive the disease is: Early use of high-efficacy
  therapies may reduce the risk of long-term disability progression in many
  people with MS.
• Lifestyle and convenience:
  • Prefer to “set it and forget it”? Twice-yearly infusions or injections (Ocrevus/Ocrevus Zunovo, Briumvi) might be appealing.
  • Want to avoid infusion centers and travel? Kesimpta’s monthly home injections might fit better.
• Other health issues: Prior or current cancers, chronic
  infections, hepatitis B, and lung or heart disease can influence which
  B-cell therapy is safest.
• Pregnancy plans: Because these drugs linger in the body for
  months, timing around pregnancy needs careful planning. Safety data are
  still evolving, but most guidelines recommend avoiding active B-cell
  therapy during pregnancy and for a period before conception.
• Insurance and cost: Coverage, copays, and availability of
  patient assistance programs can strongly influence the final choice.

Neurologists also watch for signs that a therapy isn’t working well enough
such as relapses, new MRI lesions, or disability worseningand may recommend
switching to another high-efficacy agent, sometimes within the same B-cell
class.

Risks, Monitoring, and Staying Safe on B-Cell Therapy

Because B-cell therapies affect the immune system, they require regular
monitoring and some extra precautions:

• Before treatment: Screening for hepatitis B, checking
  immunoglobulin levels, and updating vaccines (especially COVID-19, flu,
  and pneumonia) are recommended before the first dose. Live vaccines usually
  need to be given several weeks before treatment starts.
• During treatment: Your team may repeat bloodwork to monitor
  white blood cells and antibody levels and watch for infections.
• Infection risk: Respiratory infections, sinus infections,
  and skin infections are the most common. Serious infections can occur but
  are less common.
• Rare complications: Progressive multifocal
  leukoencephalopathy (PML) is a rare but serious brain infection that has
  been reported with some immunosuppressive drugs. The overall risk with
  anti-CD20 therapies appears relatively low but is taken very seriously.
• Long-term immune effects: Some people develop low
  immunoglobulin levels after years of treatment, which may prompt closer
  monitoring, dose adjustments, or switching therapies.

None of these medications cure MS, but they can dramatically reduce disease
activity and help preserve function over the long term. Your job (with your
neurologist) is to balance that benefit against the potential risks in a way
that fits your life.

Questions to Ask Your Neurologist About B-Cell Therapy

When you’re considering B-cell therapy, it can help to arrive at the clinic with a short question list, such as:

• Why are you recommending this specific B-cell therapy for my type of MS?
• How does its effectiveness compare with other high-efficacy options?
• What monitoring will I need (blood tests, MRI frequency, etc.)?
• What are my personal risk factors for infections or other side effects?
• How will this treatment affect my vaccines, travel plans, or work schedule?
• What are the costs, and are there assistance programs if I need them?
• If it doesn’t work well enough, what would the next option be?

Having these conversations early can make B-cell therapy feel less mysterious
and more like a shared, informed choice rather than something that “just
happens” to you.

Real-Life Experiences with B-Cell Therapy for MS

Clinical trials tell us about relapse rates and MRI lesions, but they don’t
always capture what it’s like to actually live on a B-cell therapy. Real-world
experiences vary a lot, but some themes come up again and again in patient
stories and support groups.

The first treatment day jitters

For people starting an infused B-cell therapy like Ocrevus or Briumvi, that
first day in the infusion chair can feel like a big deal. You often check in
early, answer a stack of questions, get IV access, receive premedications
(steroids, an antihistamine, maybe acetaminophen), and then settle in for a
long sit.

Many people describe the first infusion as “boring but emotional.” On one
hand, you’re scrolling your phone, watching shows, or working on a laptop
while the medication drips in. On the other hand, there’s a quiet, heavy
awareness: “This is a serious drug; I really have MS; this is my life now.”
Having a friend or family member drop you off, or at least staying in touch
by text, can make that day feel less overwhelming.

Adjusting to a new “normal” with infusions

After a few rounds, many people settle into an infusion routine. You learn
which snacks to pack, which hoodie is warm enough, and how you usually feel
afterward. Some people feel wiped out for a day or two with fatigue or a
“flu-ish” feeling; others bounce back quickly. Planning lighter schedules for
a day or two after infusions is a common survival strategy.

People who switch from IV Ocrevus to Ocrevus Zunovo often say that the
shorter, 10-minute injection (plus observation time) feels less disruptive
than a multi-hour infusion visit, especially if they have busy jobs or kids
at home. Instead of building your week around a hospital day, you’re more
likely to squeeze the appointment in and get back to life.

Living with monthly injections at home

With Kesimpta, the emotional experience is different. There’s usually some
anxiety around the first self-injectionespecially if you’re needle-averse
but most people adapt after a few doses. The autoinjector pen is designed to
simplify the process: you prep the site, click the device, wait for the
sound, and you’re done.

For many, the biggest benefit is independence. You don’t have to negotiate
time off work for infusions or worry about clinic capacity. On the flip side,
the responsibility for staying on schedule shifts heavily onto you. People
often rely on calendar reminders, smartphone apps, or pairing “injection day”
with a recurring event (like the first weekend of the month) to stay
consistent.

Side effects, big and small

Day-to-day side effects can range from “barely noticeable” to “this is really
messing with my week.” Injection-site reactions, mild headaches, or temporary
fatigue are common. Most people learn their personal pattern: maybe you feel
off for one evening after Kesimpta, or maybe your Ocrevus infusions predictably
knock you out for 24 hours.

Infections are a bigger deal. Sinus infections, bronchitis, or stubborn colds
can show up more often and hang around longer. Many patients become more
intentional about sleep, nutrition, hand hygiene, and avoiding obviously sick
contacts. Some say B-cell therapy turns them into “that person” who always
has hand sanitizer in the carand honestly, that’s not a bad thing.

Emotional and practical wins

There’s another side to the story: the relief of stability. People who went
from frequent relapses to zero relapses for several years on a B-cell therapy
often describe a huge emotional shift. They worry less about waking up unable
to walk, or about new MRI surprises every year. Being able to plan careers,
relationships, and travel with more confidence is a quiet but powerful win.

On a practical level, spacing treatment every six months (for infusions or
Zunovo) or standardizing life around a monthly injection day helps many
people feel like MS is “managed,” not constantly exploding into their
schedule. The disease is still therebut it’s not driving the car quite as
much.

One important reminder

Everyone’s experience with B-cell therapy is different. Some people find
these medications life-changing, with minimal side effects. Others struggle
with infections, fatigue, or anxiety and end up switching therapies. None of
the anecdotes you hear online can replace a conversation with your
neurologist, who knows your MRI history, lab results, and other health
conditions.

If you’re considering B-cell therapyor already on one and wondering what’s
nextbring your questions, your fears, and your goals to your medical team.
These drugs are powerful tools, but the most important part of the equation
is still you.

Conclusion

B-cell therapies have reshaped how we treat MS. Whether it’s twice-yearly
Ocrevus or Ocrevus Zunovo, monthly Kesimpta, or newer options like Briumvi,
these medications offer high-level control of disease activity for many
people. The “best” therapy isn’t just the most powerful on paperit’s the one
that matches your MS type, lifestyle, risk tolerance, and long-term plans.

Work closely with your neurologist, stay on top of monitoring, and don’t be
shy about sharing how you feel physically and emotionally. With the right
information and support, B-cell therapy can be more than just a complicated
drug nameit can be a key part of keeping your life and goals at the center
of your MS story.